Shares of ProQR Therapeutics rose 10% in premarket trading after it said the Food and Drug Administration had granted an orphan-drug designation to QR-1123. The experimental therapy is being tested as a treatment for vision loss caused by autosomal dominant retinitis pigmentosa (adrp), a rare eye disease. “Our goal is to develop and actively advance a pipeline of programs that can treat inherited retinal diseases like adRP in a targeted manner,” ProQR CEO Daniel de Boer said in a news release. ProQR stock is down 51% year-to-date, while the S&P 500 has gone up 24%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
- Dark day for workers as thousands lose jobs including 15,000 at Boeing rival Airbus. - July 2, 2020
- The extra $600 Americans receive in unemployment benefits ends this month — here’s what else is on the table - July 2, 2020
- Dispatches from a Pandemic: ‘You feel like you’re being social — and responsible’: Meet the people who are turning garages into mini-bars - July 2, 2020